LFG
FLNA

Larson Financial Group’s Filana Therapeutics FLNA Stock Holding History

Larson Financial Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200
Closed -$107 – 1622
2023
Q1 		$107 Buy
+200
New +$5.54K ﹤0.01% 1495

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Larson Financial Group's FLNA Position: Q1 2026 in Review

Larson Financial Group held its Filana Therapeutics (FLNA) position steady in Q1 2026 at 10 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #3587.

Larson Financial Group first reported a position in FLNA in Q3 2021 and has held it in 12 quarters since. The position peaked at $3K in Q3 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Larson Financial Group held 10 shares of Filana Therapeutics worth $17 as of Q1 2026.
  • Larson Financial Group left its Filana Therapeutics share count unchanged in Q1 2026.
  • Filana Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3587 holding.
  • Larson Financial Group first reported a position in Filana Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Larson Financial Group's Filana Therapeutics position peaked at $3K in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.